Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports

Quizartinib is a tyrosine kinase inhibitor selectively targeting the FMS-like tyrosine kinase 3 (FLT3) receptor that has been developed for the treatment of acute myeloid leukaemia (AML). The Phase 3 QuANTUM-R study investigated the efficacy of quizartinib monotherapy in patients with relapsed/refra...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez-Cuadrón, David, Rodríguez-Macías, Gabriela, Rodríguez-Veiga, Rebeca, Boluda, Blanca, Montesinos, Pau
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Practical Application
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035240/
https://www.ncbi.nlm.nih.gov/pubmed/31912423
http://dx.doi.org/10.1007/s40261-019-00881-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035240/
https://www.ncbi.nlm.nih.gov/pubmed/31912423
http://dx.doi.org/10.1007/s40261-019-00881-7

Ejemplares similares